Christopher Pieczonka, MD, director of clinical research, Crouse Health, discusses where the novel agent sabizabulin (VERU-111) would fit in the metastatic castration-resistant prostate cancer (mCRPC) paradigm if it succeeds in an ongoing phase 3 trial (NCT04844749). The study is exploring single-agent sabizabulin as a second-line treatment for patients with mCRPC.
In the video, Pieczonka says that if sabizabulin is established as a second-line option, it would then be explored in the upfront setting, most likely in combination regimens. Positive phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in mCRPC were presented during the 2021 ASCO Annual Meeting (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi: 10.1200/JCO.2021.39.15_suppl.5056).
Plant-based diets linked to lower risk of prostate cancer progression and recurrence
March 7th 2023"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.
Gene therapy EG-70 shows early promise in BCG-unresponsive NMIBC
February 27th 2023"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.
Real-world study investigates first-line avelumab maintenance for metastatic urothelial carcinoma
February 20th 2023Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.
2 Clarke Drive
Cranbury, NJ 08512